)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nuvectis Pharma
Nuvectis Pharma (NVCT) investor relations material
Nuvectis Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Ex-China rights to NXP100 (ciprocopan) and NXP200 were licensed from Haisco; ciprocopan received its first global approval in China for treatment-naive PNH in July 2026.
NXP200 received China Breakthrough Therapy Designation for recurrent or progressive high-grade BRAF V600-mutant glioma; expanded Phase 1b data were presented at ESMO in October.
Financial highlights
Q3 2026 net loss was $30.1M vs. $7.5M YoY; adjusted net loss was $5.8M excluding the $20.0M upfront license payment, $1.8M NXP900 milestone and $2.4M non-cash stock compensation.
Q3 R&D expense was $27.4M vs. $5.8M YoY, primarily reflecting license and milestone payments; G&A was $3.7M vs. $2.0M.
9M 2026 net loss was $43.1M vs. $19.1M; R&D expense was $36.2M vs. $13.1M and G&A was $8.3M vs. $6.9M.
Cash and cash equivalents were $140.7M at September 30, 2026, vs. $31.6M at December 31, 2025; estimated runway extends into 2H 2029.
Outlook and guidance
FDA update on whether China PNH clinical data can support a U.S. marketing application is expected before year-end; the U.S. regulatory path remains under discussion.
U.S. IND submissions for NXP100 and NXP200 are targeted by year-end; NXP100 trials are targeted to start as soon as possible in 2027, with NXP200 Phase 1b planned for early 2027.
China approval for NXP100 in previously anti-C5-treated PNH patients is expected in Q1 2027; China Phase 3 IgA nephropathy results are expected around April or May.
NXP900 combination-trial updates are expected in H1 2027; an investigator-sponsored pancreatic cancer combination trial is planned at two U.S. medical centers.
Additional NXP200 China solid-tumor data are expected in early 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nuvectis Pharma
- Ciprocopan’s China PNH approval anchors a three-program precision medicine pipeline.NVCT
Corporate presentation - Ciprocopan anchors a clinical pipeline with PNH validation and broad oncology opportunities.NVCTCorporate presentation
- NXP100 targets the PNH market with once-daily dosing, aiming for pivotal trials and regulatory clarity by 2027.NVCT12th Annual Cantor Fitzgerald Global Healthcare Conference
- Lead assets show strong efficacy in PNH and IgAN, with pivotal data and expansion plans ahead.NVCTH.C. Wainwright 28th Annual Global Investment Conference
- Strong clinical progress and financial position drive near-term catalysts in precision medicine.NVCTCorporate presentation
- Precision oncology firm launches $200M shelf, $75M ATM to fund pipeline; dilution risk noted.NVCTRegistration filing
- Advancing late-stage precision therapies for complement diseases and cancer with strong clinical data.NVCTCorporate presentation
- Q2 2026 net loss was $7.0M; $115M raised in July extends cash runway into 1H 2029.NVCTQ2 2026
- NXP900’s oral regimen targets resistance and unmet needs in NSCLC with a novel, well-tolerated approach.NVCTKOL Event
Next Nuvectis Pharma earnings date
Q4 202611 Feb, 2027
Nuvectis Pharma
Next Nuvectis Pharma earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nuvectis Pharma, Inc. is a biopharmaceutical company specializing in the development of precision medicines aimed at addressing significant unmet medical needs in oncology. The company's development pipeline includes two key clinical-stage drug candidates: NXP800 and NXP900. The company is headquartered in Fort Lee, New Jersey, and its shares are listed on the NASDAQ.